FIGURE 3 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors

Antitumor activity. A, Best percent change in target lesions by KIN-3248 starting dose level. Bars are color-coded by the gene (FGFR2 or FGFR3) that was altered according to the molecular report provided for study eligibility evaluation (local testing). Bars are labeled with the best overall response for each evaluable participant. X-axis is labeled with the tumor type of each participant, with the labels color-coded (black or red) to show which participants have been previously treated (*) with one or more FGFR inhibitors. Participants with documented on-target acquired resistance mutations, either by local testing or central ctDNA analysis, are indicated with distinct symbols. B, Twenty-six patients were evaluable for efficacy and were tested by central ctDNA analysis. Box and whisker plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best overall response. C, Scatter plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best % change in target lesions. X-axis direction is reversed. Linear fit with SE. Pearson R = 0.45, P = 0.021.